Why Is Oxford Nanopore Technologies PLC Up Today?

Oxford Nanopore Technologies PLC shares rose over 1.2% today, according to the supplied market data, with the shares around 160.3p.

The move follows a mixed period for the DNA and RNA sequencing specialist, whose shares have been volatile amid swings between guidance upgrades and regional Demand softness.

Today's advance may reflect renewed investor confidence in the group's underlying Revenue growth trajectory and progress toward profitability.

Key Highlights

Oxford Nanopore develops portable, real-time DNA and RNA sequencing devices, including the MinION and PromethION platforms, used across scientific research, healthcare and environmental monitoring applications.

Full-year 2025 revenue grew approximately 22% to around £223 to £224 million, slightly ahead of the group's guidance range, with broad-based growth across geographies, customer end markets and product categories.

The group has continued to make progress on its path to profitability, even as it navigates regional headwinds, including softer trading in China and the Middle East, which weighed on first-half 2026 revenue relative to consensus.

A new chief executive, Francis Van Parys, was appointed in late 2025, succeeding founder Gordon Sanghera.

About Oxford Nanopore Technologies PLC

Oxford Nanopore's nanopore-based sequencing technology enables direct, real-time analysis of DNA and RNA molecules, offering scalability and accessibility across a broad range of genetic analysis applications.

The company's technology has been widely adopted in genomic research, pathogen surveillance and increasingly in clinical and industrial applications.

For LSE:ONT, the most important factors are revenue growth across geographies and product categories, progress toward profitability, and demand trends in key markets including China and the Middle East.

Key Reasons Behind Today's Move

Today's gain follows a period of stabilisation after shares fell sharply when the group flagged a first-half revenue miss driven by weakness in China and the Middle East.

Full-year 2025 results showed revenue growth slightly ahead of guidance, providing some reassurance around the durability of underlying demand outside the affected regions.

Continued progress on cost discipline and the path to profitability has been a focus for new Leadership under chief executive Francis Van Parys.

Insider share purchases by company directors have also been read by some investors as a signal of confidence in the group's prospects.

Navigating Regional Headwinds

Oxford Nanopore's first-half 2026 trading update flagged a decline of around 16% in China revenue, reflecting enhanced export control restrictions and changes to commercial operations in the region.

Middle East revenue also fell around 14%, alongside timing effects on customer orders and contract wins in the Americas.

Management has framed these as largely regional and timing-related issues rather than a broader deterioration in underlying demand for the group's sequencing technology.

Broad-Based Growth Outside Affected Regions

Despite regional softness, Oxford Nanopore's full-year 2025 performance showed broad-based growth across geographies, customer end markets and product categories, underscoring the breadth of demand for its sequencing platforms.

Applications spanning scientific research, clinical genomics and environmental monitoring continue to provide diverse sources of revenue growth.

Continued Investment in expanding the group's product portfolio, including higher-throughput platforms, aims to capture a broader range of use cases over time.

Risks

The biggest risk for LSE:ONT is continued or worsening regional headwinds, particularly in China, where export controls and shifting commercial dynamics have already weighed on revenue.

The company remains loss-making, meaning continued execution on cost discipline is necessary to reach sustainable profitability.

Competitive pressure from other sequencing technology providers could affect Market Share and pricing over time.

Currency movements and broader macroeconomic conditions affecting research and healthcare budgets globally could also weigh on demand.

Valuation

Oxford Nanopore is typically valued on revenue growth, gross Margin trends, and progress toward profitability relative to other genomics and life sciences technology companies.

The shares have been volatile over the past year, reflecting swings in sentiment between guidance upgrades and downgrades tied to regional demand.

Sustained broad-based revenue growth and continued progress toward profitability could support a re-rating, while further regional setbacks could weigh on the shares.

What Investors Should Watch Next

Investors should monitor revenue trends in China and the Middle East for signs of stabilisation or further deterioration.

Progress toward profitability, including gross margin and operating cost trends, will remain a key focus under new leadership.

Broader adoption of the group's sequencing platforms across research, clinical and industrial applications will be an important indicator of Long-term Growth potential.

Conclusion

Oxford Nanopore's gain today reflects a degree of stabilisation after a volatile period, as investors weigh encouraging full-year growth against ongoing regional headwinds.

The group's broad-based demand across geographies and applications continues to underpin its position as a leading provider of nanopore sequencing technology.

The investment case remains tied to the durability of underlying sequencing demand, alongside the company's progress toward sustainable profitability under new leadership.